The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class available for children ...

The product, an oral RET inhibitor, was approved in 2020 by the FDA to treat adults with metastatic RET fusion-positive non-small-cell lung cancer (NSCLC), shortly after Roche paid $775 million ...

[31] XL-184 (BMS 907351, cabozantinib; Exelixis, South San Francisco, CA, USA) is an oral inhibitor of several TK receptors. The primary targets are VEGFR2, RET, c-KIT and MET, which is highly ...

Targeted therapy for thyroid cancer with BRAF and RET inhibitors has progressed to Phase II clinical trials with first results on the therapeutic response pending.